KCNA10 and familial pancreatic carcinoma: Because KCN1 inhibits a physiological process (hypoxia) that is inherent in the formation of tumors, rather than a cancer type-specific target, the agent can potentially be used to treat a variety of different cancers, including those for which there are currently no effective treatments, especially pancreatic cancer.